Ozempic and Bone Loss: What 5 Studies Actually Found — And How to Protect Yourself
The evidence is real and the risk is real. But the bone loss is driven by the weight loss — not a direct toxic effect of the drug. That distinction matters because it means the risk is preventable.
Yes — GLP-1 medications including Ozempic, Wegovy, Mounjaro, and Zepbound are linked to reductions in bone mineral density. Multiple studies confirm this. But the bone loss appears to be driven primarily by the rapid weight loss, not a direct pharmacological effect of the drug. That distinction matters enormously: it means the same strategies that protect muscle during GLP-1 therapy — resistance training, adequate protein, calcium and vitamin D — also protect bone. The risk is real and worth taking seriously. It is also largely preventable.
Why GLP-1 Therapy Affects Bone Density
Understanding the mechanism is critical because it clarifies what can and cannot be done about it. The bone loss associated with GLP-1 therapy does not appear to result from a direct pharmacological effect on bone tissue. It appears to result from two interconnected consequences of the weight loss the medications produce.
Reduced mechanical load on the skeleton
Bone is a dynamic tissue that constantly remodels itself in response to the physical demands placed on it. When you carry more body weight, your skeleton experiences more mechanical load, and bone formation is stimulated to meet that demand. When weight drops rapidly — as it does on GLP-1 therapy, where 15–21% total body weight reductions are documented — the mechanical load on bones decreases significantly. The skeleton responds by reducing bone formation, because it no longer needs to maintain the bone mass it had at a higher weight. This is not unique to GLP-1 medications — the same effect is well-documented after bariatric surgery and aggressive calorie restriction.
Nutrient deficiency from appetite suppression
GLP-1 medications reduce food intake by 30–50% for most users. When overall calorie intake drops this dramatically, the intake of bone-critical nutrients — calcium, vitamin D, magnesium, and protein — drops with it. Calcium is the primary structural mineral in bone. Vitamin D is required for calcium absorption. Protein is required for the collagen matrix that gives bone its flexibility and fracture resistance. Deficiencies in any of these accelerate the bone loss that reduced mechanical load has already initiated.
Because bone loss is driven by weight loss mechanics rather than drug toxicity, the magnitude of bone loss correlates directly with the magnitude of weight loss. Faster and larger weight loss means greater bone exposure. This is why tirzepatide users face higher risk than semaglutide users — they simply lose more weight on average.
Who Is Most at Risk
Not everyone taking GLP-1 medications will experience clinically meaningful bone density loss. Risk is significantly higher for specific groups. Understanding whether you are in one of them determines how aggressively to manage bone protection from the start of treatment.
Four Evidence-Based Strategies That Actually Work
These are not precautionary suggestions. They are evidence-based interventions that the research shows can meaningfully reduce or eliminate GLP-1-associated bone loss.
This is the single most important protective strategy, and the JAMA Network Open 2024 study proves it directly. Participants who combined exercise with GLP-1 therapy preserved bone density at the hip, spine, and forearm despite significantly larger total weight loss. Those taking GLP-1 therapy without exercise experienced measurable bone density reductions. Exercise alone or GLP-1 therapy alone did not achieve the same protection.
When muscles contract against resistance, they pull on the bones they attach to, creating the mechanical stress that stimulates osteoblast activity and bone formation. This directly counteracts the mechanical unloading effect of weight loss. Weight-bearing cardio provides some benefit, but resistance training is far more effective.
The same protocol that protects muscle on GLP-1 therapy also protects bone — compound movements, progressive overload, 2–3 sets of 8–12 reps. Read How to Prevent Muscle Loss on GLP-1 for the full training protocol.
The standard adult recommendation for calcium is 1,000mg per day, increasing to 1,200mg for women over 50 and men over 70. Because GLP-1 appetite suppression significantly reduces overall food intake, dietary calcium alone is often insufficient. Supplementation is typically necessary for postmenopausal women and older adults already at elevated baseline risk.
The best dietary calcium sources practical for GLP-1 users — easy to eat in small quantities: Greek yogurt (~200mg per serving), low-fat cottage cheese, milk, fortified plant milks, and canned sardines with bones. Leafy greens including kale and bok choy are reasonable sources, though their calcium is less bioavailable than dairy.
Vitamin D is required for calcium absorption in the gut. Without adequate vitamin D, calcium supplementation has reduced effectiveness. Because GLP-1 users are typically reducing fat intake alongside overall food intake, and vitamin D is fat-soluble, supplementation is often the most reliable route. A blood test determines current status before supplementation begins.
Protein is not just a muscle nutrient — it is a bone nutrient. The collagen matrix that gives bone its flexibility and prevents brittle fractures is approximately 90% protein. Research consistently shows higher protein intake is associated with better bone density outcomes during calorie restriction. Because GLP-1 appetite suppression makes hitting protein targets through meals alone very difficult, high-protein snacks and protein shakes distributed throughout the day are typically necessary.
Use the GLP-1 Protein Calculator to get your personalised daily target.
Should You Get a Bone Density Scan (DEXA)?
A DEXA scan is the gold standard test for measuring bone mineral density. It takes 10–20 minutes, uses minimal radiation, and provides a T-score that shows where your bone density sits relative to a healthy young adult reference population.
A baseline DEXA before starting or early in GLP-1 therapy is recommended if you have any of the following:
- Postmenopausal status
- Age over 65 (women) or 70 (men) — or earlier if other risk factors are present
- A previous fragility fracture (fracture from a fall from standing height or less)
- Family history of osteoporosis or hip fracture
- Long-term corticosteroid use
- Low body weight or low BMI
- Planned significant weight loss — more than 10% of body weight
For people without these risk factors, a baseline DEXA is not routinely indicated, but monitoring becomes more important as weight loss progresses — particularly if loss exceeds 10% of total body weight. If you are in any higher-risk category and have been on GLP-1 therapy for six months or more without a DEXA, request one at your next clinical appointment.
Five Studies — What Each One Found
Researchers analysed health records from nearly 150,000 adults with obesity and type 2 diabetes over five years. Among GLP-1 users, approximately 4% developed osteoporosis. In the non-GLP-1 group, the rate was just over 3% — roughly a 30% increase in relative risk. Osteomalacia occurred at nearly twice the rate in GLP-1 users.
Published in the Journal of Clinical Endocrinology and Metabolism, this retrospective study directly measured bone mineral density changes in 255 GLP-1 patients matched against 255 controls. After a median 17-month follow-up, the GLP-1 group showed greater total hip bone loss — particularly in non-diabetic patients experiencing the largest absolute weight reductions. Weight loss was identified as the primary driver.
A study of 255 patients specifically at high fracture risk — 75% of whom already had osteopenia or osteoporosis at baseline — found significant BMD declines over an average 34-month follow-up: lumbar spine −1.6%, femoral neck −1.8%, total hip −2.8%. The amount of bone lost was significantly correlated with the amount of weight lost (Pearson r=0.35, p<0.001). Among this high-risk group, 13% developed a new fracture after starting GLP-1 therapy.
A retrospective cohort study of over 130,000 patients with type 2 diabetes or obesity compared tirzepatide users to users of other GLP-1 medications. Tirzepatide was associated with a 44% higher risk of osteoporosis or fragility fracture and a 61% higher rate of initiating osteoporosis treatment. The authors suggest this reflects tirzepatide’s more pronounced weight loss effect.
A secondary analysis of a randomised clinical trial compared three groups: exercise alone, GLP-1 therapy alone, and GLP-1 therapy combined with exercise. Participants who combined exercise with GLP-1 therapy preserved bone density at the hip, spine, and forearm despite significantly larger total weight loss. Those taking GLP-1 therapy without exercise experienced measurable bone density reductions. This is the most clinically important finding in the bone loss literature — a modifiable intervention that directly counters the risk.
Bone Protection Quick Reference
| Strategy | Target | Why it works |
|---|---|---|
| Resistance training | 2–3 sessions per week, full body | Creates mechanical load on bone, directly stimulating osteoblast activity and counteracting weight-loss-induced unloading |
| Calcium | 1,000–1,200mg daily from food and supplements | Primary structural mineral in bone. GLP-1 appetite suppression typically reduces dietary intake below adequate levels |
| Vitamin D | 600–1,000 IU daily; check blood levels | Required for calcium absorption — without it, calcium supplementation is far less effective |
| Protein | 1.2–2.0g per kg body weight daily | Maintains the collagen matrix that gives bone its fracture resistance; also preserves muscle, which protects bone indirectly |
| DEXA scan | Baseline for high-risk groups before or early in treatment | Identifies pre-existing bone density issues before GLP-1 therapy begins; enables proactive monitoring |
| Rate of weight loss | Gradual loss 0.5–1kg per week preferred | Greater weight loss correlates directly with greater bone density reduction — moderate deficit is safer for bone |
Putting the Risk in Perspective
The bone loss risk is real. It is also modest in absolute terms for most people. A 30% increase in relative risk sounds alarming, but it translates from a 3.1% baseline rate to approximately a 4% rate over five years. For the vast majority of GLP-1 users who are not postmenopausal, over 65, or already osteopenic, the absolute fracture risk from GLP-1 therapy is small.
GLP-1 medications have substantial documented benefits — 20% reductions in major cardiovascular events in the SELECT trial, significant improvements in heart failure symptoms, reductions in sleep apnoea, and meaningful sustained weight loss that improves metabolic health across dozens of markers. The bone loss data argues not for stopping the medication, but for managing it properly: resistance training, adequate nutrition, and appropriate monitoring for those at higher risk.
Bone loss is one of several longer-term considerations for GLP-1 users. The muscle loss guide covers the most clinically significant risk. The Signs You Are Not Eating Enough on GLP-1 article is particularly relevant — chronic under-eating is the primary driver of both muscle loss and bone loss on GLP-1 therapy.
Frequently Asked Questions
Yes — GLP-1 medications are associated with reductions in bone mineral density, primarily as a consequence of rapid weight loss rather than a direct drug effect. A 2025 AAOS study of nearly 150,000 adults found a roughly 30% increase in relative osteoporosis risk over five years. A February 2026 Weill Cornell study confirmed significant total hip bone density declines. The key finding: bone loss correlates with weight loss magnitude, not drug dosage — meaning protective strategies like resistance training and adequate nutrition can significantly reduce the risk.
A 2025 Endocrine Society study of 255 patients on semaglutide or tirzepatide found declines across all bone sites over an average 34-month follow-up: lumbar spine −1.6%, femoral neck −1.8%, total hip −2.8%. The amount of bone lost was significantly correlated with the amount of weight lost — meaning faster and larger weight loss was linked to greater bone density reduction. People who combined GLP-1 therapy with exercise in the JAMA Network Open 2024 study showed zero bone density loss despite larger total weight loss.
Highest risk: postmenopausal women; adults over 65; people with existing osteopenia or osteoporosis; people losing weight rapidly (more than 0.5–1kg per week). Moderate risk: people not doing resistance training; people with inadequate calcium, vitamin D, or protein intake; people with low BMI or previous fragility fractures. Tirzepatide users may face higher risk than semaglutide users due to greater average weight loss.
Yes. The JAMA Network Open 2024 study found that combining exercise with GLP-1 therapy preserved bone density completely — at the hip, spine, and forearm — despite significant weight loss. Four strategies together provide the strongest protection: resistance training 2–3 times per week; calcium 1,000–1,200mg daily; vitamin D 600–1,000 IU daily; protein at least 1.2g per kg body weight per day. These are the same strategies that protect muscle during GLP-1 therapy.
A baseline DEXA is recommended for people with risk factors including postmenopausal status, a previous fragility fracture, family history of osteoporosis, long-term corticosteroid use, low BMI, or age over 65. For people without these risk factors, a DEXA before starting is not routinely indicated — but monitoring becomes more important if significant weight loss occurs. If you are in a high-risk category and have been on GLP-1 therapy for six months without a DEXA, request one at your next appointment.
A November 2025 TriNetX study of over 130,000 patients found tirzepatide was associated with a 44% higher risk of osteoporosis or fragility fracture compared to other GLP-1 receptor agonists. The authors suggest this reflects tirzepatide’s more pronounced weight loss — patients typically lose more total weight on tirzepatide, which amplifies mechanical unloading of bones. The same four protective strategies apply to both medications, but the greater the weight loss, the more important bone protection becomes.
Yes. Wegovy (semaglutide 2.4mg) causes the same pattern of bone density reduction as Ozempic, driven by weight loss rather than a direct drug effect. The Wegovy FDA label specifically notes higher fracture rates in women: 1% versus 0.2% in the placebo group. Because Wegovy produces larger average weight loss than lower-dose Ozempic, the bone loss risk may be somewhat greater on Wegovy. The same four protective strategies — resistance training, calcium, vitamin D, protein — apply equally.
Research & References
- Liu Y, et al. MON-817 Association of Semaglutide and Tirzepatide Use on Bone Density and Fracture Risk in Obese Patients with and without Diabetes. Journal of the Endocrine Society. 2025;9(Suppl 1):bvaf149.558.
- Liu Y, Walzer D, Schmitz S, et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. Journal of Clinical Endocrinology and Metabolism. 2026;dgag052.
- Horneff J, et al. GLP-1s may increase risk of osteoporosis and gout. American Academy of Orthopaedic Surgeons Annual Meeting, 2025.
- Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Network Open. 2024;7(5):e2416775.
- Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk. eClinicalMedicine. 2024;72:102624.
- TriNetX cohort study. Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(1):104284.
- Karam L, et al. Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Osteoporosis International. 2025.